COBAS Human papillomavirus (HPV) test is a qualitative in-vitro screening and risk stratification test for detection of HPV DNA in patient specimens which is designed to provide precise and accurate information that would help clinician with actionable results and also a management value. This is the only FDA approved test for ASC-US reflex, adjunctive and co-testing with PAP test and first line as the primary screening. It’s the only clinically validated, FDA-approved and CE-marked assay that offers three high-risk tests in one (3 in 1 test result) by identifying (types) HPV 16 and HPV 18, while simultaneously detecting the rest of the 12 hrHPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). Having immediate information about your risk of cervical cancer can help you and your doctor determine what next steps to take.
Why Cobas HPV test?
- Confidence of screening for DNA present at all stages of disease progression
- Protection from False-Negatives, with Internal Cellular Control (to check integrated sample quantity and quality control)
- Protection from False-Positives, with no cross-reactivity with low-risk genotypes unlike other HPV tests.
- Helps reduce missed disease, PAP screening alone can miss nearly half the cases of cervical disease in a single round of screening.
- Delivers three results from a single test and eliminates the need for reflex genotyping
- Greater reassurance for the negative test when compared to PAP test